Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziming Li

Showing results (191-200 of 225) with videos related to

Pageof 23
Sort By:
Cancer Science|December 20, 2021
NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapyHui Wang, Liliang Xia, Cheng-Cheng Yao, et al.
Experimental Hematology & Oncology|May 17, 2024
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancerHanbo Pan, Yu Tian, Siyu Pei, et al.
The Annals of Thoracic Surgery|October 6, 2025
Lobar vs Sublobar Resection for Clinical Stage IA1-2 Non-Small Cell Lung Cancer With Tumor Spread Through Air SpacesHanbo Pan, Yu Tian, Hang Chen, et al.
Signal Transduction and Targeted Therapy|December 15, 2024
Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)Xinghao Ai, Bo Jia, Zhiyi He, et al.
Updates in Surgery|June 21, 2025
Lobar versus sub-lobar resection for clinical stage IA (≤ 2 cm) lung neuroendocrine tumor with spread through air spaces: a multi-center studyHanbo Pan, Hang Chen, Weicheng Kong, et al.
The Lancet. Oncology|June 15, 2026
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialZiming Li, Jie Hu, Jianhua Chen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 13, 2025
Comparison between sub-lobar resection and lobar resection for clinical stage IA (tumor size ≤ 2 cm) lung invasive mucinous adenocarcinoma with tumor spread through air spaces: A multi-center real-world studyHanbo Pan, Weicheng Kong, Hui Yin, et al.
Journal of Translational Internal Medicine|July 2, 2026
Molecular residual disease-based novel modality of postoperative management for non-small-cell lung cancer (REMODEL): Protocol for a prospective multicenter studyXiaoqiu Yuan, Ruoyi Jin, Yunchu Wei, et al.
International Journal of Surgery (London, England)|August 22, 2024
Early outcomes of minimally invasive surgery versus thoracotomy for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a multi-center real-world studyHanbo Pan, Hang Chen, Zhen Ge, et al.
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
Pageof 23

Showing results (191-200 of 225) with videos related to

Sort By:
Pageof 23
Cancer Science|December 20, 2021
NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapyHui Wang, Liliang Xia, Cheng-Cheng Yao, et al.
Experimental Hematology & Oncology|May 17, 2024
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancerHanbo Pan, Yu Tian, Siyu Pei, et al.
The Annals of Thoracic Surgery|October 6, 2025
Lobar vs Sublobar Resection for Clinical Stage IA1-2 Non-Small Cell Lung Cancer With Tumor Spread Through Air SpacesHanbo Pan, Yu Tian, Hang Chen, et al.
Signal Transduction and Targeted Therapy|December 15, 2024
Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)Xinghao Ai, Bo Jia, Zhiyi He, et al.
Updates in Surgery|June 21, 2025
Lobar versus sub-lobar resection for clinical stage IA (≤ 2 cm) lung neuroendocrine tumor with spread through air spaces: a multi-center studyHanbo Pan, Hang Chen, Weicheng Kong, et al.
The Lancet. Oncology|June 15, 2026
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialZiming Li, Jie Hu, Jianhua Chen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 13, 2025
Comparison between sub-lobar resection and lobar resection for clinical stage IA (tumor size ≤ 2 cm) lung invasive mucinous adenocarcinoma with tumor spread through air spaces: A multi-center real-world studyHanbo Pan, Weicheng Kong, Hui Yin, et al.
Journal of Translational Internal Medicine|July 2, 2026
Molecular residual disease-based novel modality of postoperative management for non-small-cell lung cancer (REMODEL): Protocol for a prospective multicenter studyXiaoqiu Yuan, Ruoyi Jin, Yunchu Wei, et al.
International Journal of Surgery (London, England)|August 22, 2024
Early outcomes of minimally invasive surgery versus thoracotomy for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a multi-center real-world studyHanbo Pan, Hang Chen, Zhen Ge, et al.
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
Pageof 23